Brought to you by 
MacroGenics closes $30.5mm Series B venture round
26 Oct 2012
Executive Summary
MacroGenics (developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases) has completed its $30.5mm Series B venture round. Alta Partners and TPG Ventures led the round and were joined by new investors Mithra Group, Red Abbey Venture Partners, Emerging Technology Partners. Returning backers InterWest Partners, MPM Capital, OrbiMed, Cogene Biotech Ventures, Vivo Ventures, and Hunt Ventures also participated.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MacroGenics closes $30.5mm Series B venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice